Filter Results:
(1,440)
Show Results For
- All HBS Web
(1,440)
- People (1)
- News (375)
- Research (870)
- Events (5)
- Multimedia (25)
- Faculty Publications (421)
Show Results For
- All HBS Web
(1,440)
- People (1)
- News (375)
- Research (870)
- Events (5)
- Multimedia (25)
- Faculty Publications (421)
- 01 Sep 2023
- News
Money Does Grow on (Family) Trees
For 17 years, Andre Kearns (MBA 1999) has been tracing his family tree. One by one, he has added branches, grounding himself in a long and sometimes complicated lineage. Through family stories, forgotten heirlooms, and vital records, Kearns has traveled back through... View Details
- Web
Topics - HBS Working Knowledge
Browse All topics Accounting Audits (3) Accounting (119) Acquisition (20) Activity Based Costing and Management (2) Adaptation (7) Adoption (3) Advertising Campaigns (6) Advertising (77) Agency Theory (3) Age (3) Agreements and... View Details
- Article
Treatment Of Opioid Use Disorder Among Commercially Insured U.S. Adults, 2008–17
By: Karen Shen, Eric Barrette and Leemore S. Dafny
There is abundant literature on efforts to reduce opioid prescriptions and misuse, but comparatively little on the treatment provided to people with opioid use disorder (OUD). Using claims data representing 12–15 million nonelderly adults covered through commercial... View Details
Keywords: Opioid Treatment; Medication-assisted Treatment; Substance Use Disorder; Private Insurance; Health Disorders; Health Care and Treatment; Insurance; United States
Shen, Karen, Eric Barrette, and Leemore S. Dafny. "Treatment Of Opioid Use Disorder Among Commercially Insured U.S. Adults, 2008–17." Health Affairs 39, no. 6 (June 2020): 993–1001.
- Web
Leadership - Faculty & Research
Measurement ; Time-Driven Activity-Based Costing ; Health Care and Treatment ; Business Strategy ; Leading Change ; Decisions ; Transformation ; Service Delivery ; Adoption ; Value ; View Details
- 07 Feb 2022
- Research & Ideas
Digital Transformation: A New Roadmap for Success
digital-first incumbents struggle to make the necessary longer-term investments when their investors focus on shorter-term metrics, participants say. At the same time, companies must deliver value at speed. They’re cutting costs through... View Details
- 2023
- Working Paper
Are Hospital Quality Indicators Causal?
By: Amitabh Chandra, Maurice Dalton and Douglas O. Staiger
Hospitals play a key role in patient outcomes and spending, but efforts to improve their quality are hindered because we do not know whether hospital quality indicators are causal or biased. We evaluate the validity of commonly used quality indicators, such as... View Details
Keywords: Quality; Health Care and Treatment; Measurement and Metrics; Outcome or Result; Health Industry
Chandra, Amitabh, Maurice Dalton, and Douglas O. Staiger. "Are Hospital Quality Indicators Causal?" NBER Working Paper Series, No. 31789, October 2023.
- 16 Nov 2021
- HBS Case
How a Company Made Employees So Miserable, They Killed Themselves
Though the company had already reduced its headcount by tens of thousands, its fixed costs remained higher than those of some competitors, so Lombard vowed to cut an additional 22,000 people. To reach its downsizing goal, Lombard told 200... View Details
Keywords: by Michael Blanding
- 24 Feb 2022
- Op-Ed
Want to Prevent the Next Hospital Bed Crisis? Enlist the SEC
billing rule that hospitals had ignored, it imposed a tangle of new requirements and directed the US Department of Health and Human Services (HHS) to help prevent excess out-of-network charges. And consider the HHS’s multimillion dollar... View Details
- 21 Oct 2008
- First Look
First Look: October 21, 2008
Working PapersCan Higher Prices Stimulate Product Use? Evidence from a Field Experiment in Zambia (revised) Authors:Nava Ashraf, James Berry, and Jesse M. Shapiro Abstract The controversy over whether and how much to charge for health... View Details
Keywords: Martha Lagace
- July 2021
- Article
Electronic Trace Data and Legal Outcomes: The Effect of Electronic Medical Records on Malpractice Claim Resolution Time
By: Sam Ransbotham, Eric Overby and Michael C. Jernigan
Information systems generate copious trace data about what individuals do and when they do it. Trace data may affect the resolution of lawsuits by, for example, changing the time needed for legal discovery. Trace data might speed resolution by clarifying what events... View Details
Keywords: Analytics and Data Science; Lawsuits and Litigation; Digital Transformation; Welfare; Health Industry
Ransbotham, Sam, Eric Overby, and Michael C. Jernigan. "Electronic Trace Data and Legal Outcomes: The Effect of Electronic Medical Records on Malpractice Claim Resolution Time." Management Science 67, no. 7 (July 2021): 4341–4361.
- 02 Sep 2015
- What Do You Think?
What's Wrong With Amazon’s Low-Retention HR Strategy?
the opportunity to earn high compensation--but jobs that often become too demanding for some employees, particularly those with health problems or family obligations. Former employees complained about bosses who lacked empathy for... View Details
- 01 Mar 2024
- News
Vital Signs
Image by Edmon De Haro Illustration by Edmon De Haro The signs of strain were there long before the pandemic: Health care workers had been managing under tremendous pressures while working long hours in understaffed hospitals. Then COVID unleashed an unprecedented... View Details
- Web
Publications - Institute For Strategy And Competitiveness
value-based health care and how a motivated team can undertake a cost measurement project in their own institution. January 2020 Academic Medicine Value Based Health Care in... View Details
- 23 Jan 2008
- First Look
First Look: January 23, 2008
Molded) grommet, was supported heavily by the product development group because it was simpler to design and improved the leak seat. Process development was against using it because it cost more, complicated the manufacturing process, and... View Details
Keywords: Martha Lagace
- Web
Systems Integration - Institute For Strategy And Competitiveness
Measure Outcomes & Cost for Every Patient Aligning Reimbursement with Value Systems Integration Geography of Care Information Technology Systems Integration Systems Integration Effectively integrated care in multiple locations is an... View Details
- 18 Jul 2023
- News
The First Five Years: Brooke Biederman (MBA 2019)
work in watches. Next, Discovery, a South African health care company, incentivizes healthy behavioral change that leads to fewer claims and lower premiums for customers as the company's cost to serve them... View Details
Keywords: Robert Bochnak
- 21 Feb 2018
- Research & Ideas
When a Competitor Abandons the Market, Should You Advance or Retreat?
Administration. He looked most closely at decisions made during phase two clinical trials—the period when diseased patients are treated with the test drug and results are compared with patients randomly receiving a placebo. The trials can last months or years and View Details
- 01 Sep 2023
- News
Solving for Z
Benefits Chen and her colleagues have also seen significant demand for mental health benefits among their youngest employees—a reflection of this generation’s interest in health and wellness in general, and... View Details
- April 2017
- Supplement
Imprimis (B)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A). It describes the company’s decision to enter into the pharmaceutical compounding business in 2013–2014. Imprimis purchased a compounded ophthalmological medication called Dropless Therapy, which was injected into patients’... View Details
Keywords: Healthcare; Drug Compounding; Drug Development; Pharmaceuticals; Small Business; Decision-making, Business Model; Mark Baum; Imprimis; Decision Making; Strategy; Health Care and Treatment; Policy; Pharmaceutical Industry; United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (B)." Harvard Business School Supplement 717-496, April 2017.
- July 2019
- Article
The Impact of Price Regulation on the Availability of New Drugs in Germany
By: Ariel Dora Stern, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim and Ameet Sarpatwari
The 2011 German Pharmaceutical Market Restructuring Act (“AMNOG”) subjected branded, non-rare disease drugs to price regulation based on an assessment of their clinical benefit. Assessment outcomes range from “major added benefit” to “less benefit than the appropriate... View Details
Keywords: Regulation; Pharmaceuticals; Healthcare; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Germany
Stern, Ariel Dora, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim, and Ameet Sarpatwari. "The Impact of Price Regulation on the Availability of New Drugs in Germany." Health Affairs 38, no. 7 (July 2019): 1182–1187.